Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat Toby M. Maher1,2* and Mary E. Strek3 Correspondence: t.maher@rbht.nhs.uk1National Institute for Health Research Respiratory Clinical Research Facility, Royal Brompton and Harefield NHS Foundation Trust, Sydney Street, London,SW3 6NP, UK2Fibrosis Research Group, National Heart and Lung Institute, Imperial College, Cale Street, London SW3 6LY, UKFull list of […]
Month: September 2022
Mitochondrial Quality Control in COPD and IPF
Mitochondrial Quality Control in COPD and IPF Hiromichi Hara * ID , Kazuyoshi Kuwano and Jun Araya Division of Respiratory Diseases, Department of Internal Medicine, The Jikei University School of Medicine,Tokyo 105-8461, Japan; kkuwano@jikei.ac.jp (K.K.); araya@jikei.ac.jp (J.A.)Correspondence: hirohara@jikei.ac.jp; Tel.: +81-3-3433-1111; Fax: +81-3-3433-1020Published: 24 July 2018 Abstract: Mitochondria play important roles in the maintenance of intracellular […]
Idiopathic Pulmonary Fibrosis (IPF): An Overview
Idiopathic Pulmonary Fibrosis (IPF): An Overview Shaney L. Barratt 1,2,*, Andrew Creamer 1, Conal Hayton 3 and Nazia Chaudhuri 3 1 Bristol Interstitial Lung Disease Service, North Bristol NHS Trust, Bristol BS10 5NB, UK;andrew.creamer@nbt.nhs.uk2 Academic Respiratory Unit, University of Bristol, Bristol BS16 1QY, UK3 North West Interstitial Lung Disease Unit, Manchester University NHS Foundation Trust, […]
UK Petition, March 2023
Increase funding for treatment of pulmonary fibrosis & interstitial lung disease Ask the Government to prioritise funding for Pulmonary Fibrosis (PF) and interstitial lung disease services. PF is terminal and kills approximately 8,000 people a year. It has a survival rate worse than many cancers. Increasing funding and creating a care pathway equal to cancer […]
Pulmonary Fibrosis Research and Education Hub
Welcome to the Pulmonary Fibrosis Research and Education Hub which is run and maintained by the Natonal Wellbeing Service Ltd.